A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo - PubMed (original) (raw)
Comparative Study
A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
R Morishita et al. Proc Natl Acad Sci U S A. 1995.
Abstract
The application of DNA technology to regulate the transcription of disease-related genes in vivo has important therapeutic potentials. The transcription factor E2F plays a pivotal role in the coordinated transactivation of cell cycle-regulatory genes such as c-myc, cdc2, and the gene encoding proliferating-cell nuclear antigen (PCNA) that are involved in lesion formation after vascular injury. We hypothesized that double-stranded DNA with high affinity for E2F may be introduced in vivo as a decoy to bind E2F and block the activation of genes mediating cell cycle progression and intimal hyperplasia after vascular injury. Gel mobility-shift assays showed complete competition for E2F binding protein by the E2F decoy. Transfection with E2F decoy inhibited expression of c-myc, cdc2, and the PCNA gene as well as vascular smooth muscle cell proliferation both in vitro and in the in vivo model of rat carotid injury. Furthermore, 2 weeks after in vivo transfection, neointimal formation was significantly prevented by the E2F decoy, and this inhibition continued up to 8 weeks after a single transfection in a dose-dependent manner. Transfer of an E2F decoy can therefore modulate gene expression and inhibit smooth muscle proliferation and vascular lesion formation in vivo.
Similar articles
- An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, Dzau VJ. Tomita N, et al. Am J Physiol. 1998 Aug;275(2):F278-84. doi: 10.1152/ajprenal.1998.275.2.F278. Am J Physiol. 1998. PMID: 9691019 - Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, Tomita N, Amano J, Kaneda Y, Ogihara T, Takamoto S, Isobe M. Kawauchi M, et al. Circ Res. 2000 Nov 24;87(11):1063-8. doi: 10.1161/01.res.87.11.1063. Circ Res. 2000. PMID: 11090553 - Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Ehsan A, et al. J Thorac Cardiovasc Surg. 2001 Apr;121(4):714-22. doi: 10.1067/mtc.2001.111204. J Thorac Cardiovasc Surg. 2001. PMID: 11279413 - E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
Mann MJ. Mann MJ. Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):171-6. doi: 10.1089/oli.1.1998.8.171. Antisense Nucleic Acid Drug Dev. 1998. PMID: 9593059 Review. No abstract available. - Therapeutic applications of transcription factor decoy oligonucleotides.
Mann MJ, Dzau VJ. Mann MJ, et al. J Clin Invest. 2000 Nov;106(9):1071-5. doi: 10.1172/JCI11459. J Clin Invest. 2000. PMID: 11067859 Free PMC article. Review. No abstract available.
Cited by
- STAT3 Decoy Oligodeoxynucleotides Suppress Liver Inflammation and Fibrosis in Liver Cancer Cells and a DDC-Induced Liver Injury Mouse Model.
Choi HJ, Kim YA, Ryu J, Park KK, Lee SJ, Kim BS, Song JE, Kim JD. Choi HJ, et al. Molecules. 2024 Jan 25;29(3):593. doi: 10.3390/molecules29030593. Molecules. 2024. PMID: 38338338 Free PMC article. - Drug-Coated Balloon versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis: A Systematic Review and Meta-Analysis.
Isaji T, Hosoi Y, Kogure K, Ichikawa Y, Fujimaki K, Ikezoe T, Nunokawa M, Kubota H. Isaji T, et al. J Clin Med. 2022 Dec 22;12(1):87. doi: 10.3390/jcm12010087. J Clin Med. 2022. PMID: 36614884 Free PMC article. Review. - Cis-regulatory decoy disrupts autorepression: a potential escape-resistant anti-viral therapy.
Hu J, Min Y, Sun X. Hu J, et al. Signal Transduct Target Ther. 2022 Sep 27;7(1):338. doi: 10.1038/s41392-022-01187-5. Signal Transduct Target Ther. 2022. PMID: 36167795 Free PMC article. No abstract available. - PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
He M, Cao C, Ni Z, Liu Y, Song P, Hao S, He Y, Sun X, Rao Y. He M, et al. Signal Transduct Target Ther. 2022 Jun 9;7(1):181. doi: 10.1038/s41392-022-00999-9. Signal Transduct Target Ther. 2022. PMID: 35680848 Free PMC article. Review. - Diverse role of decoys on emergence and precision of oscillations in a biomolecular clock.
Dey S, Singh A. Dey S, et al. Biophys J. 2021 Dec 21;120(24):5564-5574. doi: 10.1016/j.bpj.2021.11.013. Epub 2021 Nov 11. Biophys J. 2021. PMID: 34774502 Free PMC article.
References
- N Engl J Med. 1994 May 19;330(20):1431-8 - PubMed
- Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8474-8 - PubMed
- EMBO J. 1987 Jun;6(6):1643-51 - PubMed
- Nucleic Acids Res. 1987 Aug 25;15(16):6419-36 - PubMed
- EMBO J. 1987 Jul;6(7):2061-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous